Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Amir Farrokh Heshmatpour
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5
- Beta
- 0.50
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -34.64
Financials
NTHI has only 7 quarterly periods on file — the charts below show the full history available.
Revenue
$0.00-100.0%Net Income
$-4.44MEBITDA
$-4.34MFree Cash Flow
$-5.09MEPS (diluted)
$-0.28Shares Outstanding (diluted)
25.78M+42.2%Operating Expenses
$0.00Cash & Debt
$6.17MReturn of Capital
$5.79MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $40.0K | $-62.15M | $-3.23 |
Valuation
NTHIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
10-85.71%Social Signal Score
Mentions (29)
- Newsglobenewswire.com·9d ago·Negative
NeOnc Showcases Two Brain Cancer Drug Programs at SNO as FDA Meetings Approach NeOnc (NASDAQ: NTHI) to present findings from 2 investigational brain cancer programs at the 31st Annual Meeting of the Society for Neuro-Oncology (SNO)
View source ↗ - Newsglobenewswire.com·10d ago·Positive
…ead of FDA Discussions and Two Key Brain Cancer Data Presentations DENVER, Nov. 12, 2026 (GLOBE NEWSWIRE) -- ( 247MarketNews ) — NeOnc Technologies Holdings (NASDAQ: NTHI) is heading into a potentially important period for its clinical programs, with additional insider purchases coinciding with a newly announced FDA meeting that could help determine the development pathway for its investigational brain cancer therapy, NEO100. Two Form 4 filings dated November 12 add important detail to the compa…
View source ↗ - Newsglobenewswire.com·13d ago·Positive
…nc CEO Adds Another 70,000 Shares as Insider Buying Continues DALLAS, Nov. 09, 2026 (GLOBE NEWSWIRE) -- (www.InvestorsTape.com) — NeOnc Technologies Holdings (NASDAQ:NTHI) CEO Amir Heshmatpour has purchased another 70,000 shares of the company's common stock for approximately $230,510, according to a newly filed SEC Form 4. The transactions took place on November 5 and 6, with Heshmatpour purchasing 30,000 shares at a weighted average price of approximately $3.17 on the first day and another 40,…
View source ↗ - Newsglobenewswire.com·17d ago·Neutral
…nancial Results and Highlights Recent Corporate and Clinical Progress CALABASAS, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced financial results for the third quarter ended September 30, 2026, and highlighted recent corporate and clinical progress, including the upcoming presentation of data from its NEO…
View source ↗ - Newsglobenewswire.com·23d ago·Negative
… 2026 (GLOBE NEWSWIRE) -- ( 247MarketNews.com ) — In a market where the latest whizbang trends often dominate investor attention, NeOnc Technologies Holdings (NASDAQ:NTHI) is pursuing something considerably more meaningful: advancing potential treatments for some of the most difficult-to-treat brain cancers while building a clinical development program that could eventually reach hundreds of patients internationally. Now, the company is putting some impressive numbers behind that ambition.
View source ↗ - Newsglobenewswire.com·27d ago·Negative
…nsion with 500 Patients Across 30 Hospitals in Three Countries DENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com ) — NeOnc Technologies Holdings (NASDAQ: NTHI) is setting its sights on a substantially larger international clinical effort, outlining plans for a trial targeting approximately 500 patients across 30 hospitals in three countries during a discussion on Health Uncensored with Dr. Drew, on Fox Business Network. The proposed expansion brings fresh attention to NeOnc's effort …
View source ↗ - Newsglobenewswire.com·30d ago·Positive
NeOnc Breaks Through Key Levels, as Brain-Cancer Stock's Catalysts Continue DENVER, Oct. 23, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — NeOnc Technologies Holdings (NASDAQ:NTHI) cleared several key resistance levels, on strong trading volume, delivering a potentially important technical signal for a stock that recently tested lows near $2.50. The breakout marks a significant development from its recent chart snapshots.
View source ↗ - Newsglobenewswire.com·31d ago·Negative
NeOnc Heads to Fox Business as Brain Cancer Milestones Put Its Mission in the Spotlight NeOnc (NASDAQ: NTHI) is taking its brain cancer story to Fox Business Network when several developments put the clinical-stage biotech in the spotlight
View source ↗ - Newsnewsfilecorp.com·32d ago·Neutral
NeOnc's Brain Cancer Efforts Bring Hope as FDA Meeting Approaches Compassionate care for children in Abu Dhabi, a new research MoU and a senior banking appointment add momentum to NeOnc's development story Houston, Texas--(Newsfile Corp. - October 21, 2026) - As NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) prepares for an upcoming FDA meeting, its work in Abu Dhabi is bringing that human side of biotechnology into focus. Technology today can feel like magic.
View source ↗ - Newsglobenewswire.com·32d ago·Neutral
NeOnc Deepens Abu Dhabi Research Ties as Its Brain Cancer Story Moves Forward DENVER, Oct. 21, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com ) — “I wish someone had told me about that company.” That is a familiar reaction when a stock attracts attention after investors have spent months overlooking it.
View source ↗ - Newsglobenewswire.com·33d ago·Negative
Forget the Ugly Sweaters and Ugly Charts, NeOnc is Ready for Catalyst Season DENVER, Oct. 20, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com ) -- At an ugly-sweater party, the one with the most flair gets everyone talking. On Wall Street, attention can shift just as quickly when a battered chart meets a fresh set of corporate developments and an approaching regulatory milestone.
View source ↗ - Newsglobenewswire.com·39d ago·Negative
NeOnc Strengthens Boardroom Firepower as Abu Dhabi Opens a New Path for Brain Cancer Drug Development NeOnc (NASDAQ:NTHI) is strengthening its boardroom, as its clinical-development progress seeks to advance treatments for some of the most difficult cancers
View source ↗ - Newsglobenewswire.com·39d ago·Neutral
NeOnc Technologies Appoints Ali Alabedin to Its Board of Directors CALABASAS, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company developing therapies for central nervous system cancers, today announced the appointment of Ali Alabedin to its Board of Directors, effective October 9, 2026.
View source ↗ - Newsglobenewswire.com·46d ago·Positive
NeOnc among Names with 2026 Breakthroughs that Offer New Hope in the Fight Against Cancer DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- ( www.247marketnews.com )-- For patients facing cancer, progress ultimately comes down to a deeply personal question: Can treatment give them more time? A series of developments reported during 2026 is providing new reasons for hope.
View source ↗ - Newsglobenewswire.com·47d ago·Positive
NeOnc's FDA Catalyst Run Could Give NTHI a Serious Jolt DENVER, Oct. 06, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com ) -- A fall calendar is bringing NeOnc Technologies Holdings' (NASDAQ: NTHI) investigational brain-cancer programs into focus. Anticipation is building as Roth Capital's recent Buy initiation adds another Wall Street voice to the NTHI story.
View source ↗ - Newsglobenewswire.com·55d ago·Negative
Powerful NeOnc Brain Cancer Pipeline Advances NeOnc (NASDAQ: NTHI) is scheduled to meet with the FDA for an in-person End-of-Phase 1 Type B meeting covering its experimental brain-cancer drug NEO212.
View source ↗ - Newsglobenewswire.com·59d ago·Neutral
NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst DENVER, Sept. 24, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com ) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has picked up fresh Wall Street coverage at a pivotal moment for its experimental brain-cancer pipeline.
View source ↗ - Newsglobenewswire.com·62d ago·Neutral
NeOnc Charting New Nasal Route to Treating Brain Cancer DENVER, Sept. 21, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – NeOnc Technologies Holdings' (NASDAQ: NTHI) NEO100 deserves attention; not just because its Phase 2a study has suddenly solved brain cancer, but because it is testing a different answer to one of the field's oldest problems.
View source ↗ - Newsglobenewswire.com·67d ago·Positive
NeOnc's $629K Insider Buying Spree Follows Breakthrough Data and Now All Eyes Turn to the FDA DENVER, Sept. 16, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com ) -- NeOnc Technologies Holdings (NASDAQ: NTHI) executives put even more personal capital behind the company, following positive Phase 2a results for its experimental brain-cancer therapy NEO100.
View source ↗ - Newsglobenewswire.com·69d ago·Positive
Insiders Continue Buying, as NeOnc Moves NEO100 Toward Its Next Regulatory Test DENVER, Sept. 14, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ: NTHI) is sending investors a signal that is impossible to ignore.
View source ↗ - Newsglobenewswire.com·75d ago·Negative
NeOnc' Phase 2 Data Could Put Cancer on the Ropes DENVER, Sept. 08, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – For NeOnc Technologies Holdings (NASDAQ: NTHI), the Phase 2a question has been answered.
View source ↗ - Newsglobenewswire.com·86d ago·Neutral
NeOnc's Phase 2A Success Could Set the Stage for Something Much Bigger DENVER, Aug. 28, 2026 (GLOBE NEWSWIRE) -- For NeOnc Technologies Holdings (NASDAQ: NTHI), the most important part of the NEO100 story may no longer be whether the company can produce a meaningful signal in recurrent brain cancer. After its latest Phase 2a readout, the bigger move is whether those results can support a credible path toward registration.
View source ↗ - Newsglobenewswire.com·88d ago·Positive
NeOnc's Clinical Story Is Now the Main Event DENVER, Aug. 26, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has reached a point where the market conversation can move toward a much more consequential question: What happens if NEO100's clinical results translate into a viable regulatory pathway for a difficult-to-treat form of brain cancer? On August 12, NeOnc reported positive topline Phase 2a results from its NEO100-01 study in patients with recurrent or progressive Grade …
View source ↗ - Newsglobenewswire.com·96d ago·Positive
NeOnc Technologies- Talk Is Cheap, Insider Buying Isn't DENVER, Aug. 18, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has just added another potentially important element to an already potent story: its CEO, Amir Heshmatpour, is continuing to buy shares on the open market. According to the Form 4 transaction information provided by the company's latest filing, Heshmatpour purchased 12,000 NTHI shares on August 14 at an average price of $3.7883 and an…
View source ↗ - Newsglobenewswire.com·97d ago·Neutral
NTHI's Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results NeOnc's (NASDAQ:NTHI) Phase 2a results for NEO100 in recurrent IDH1-mutant high-grade glioma make its Nasdaq Global Market listing way more interesting
View source ↗ - Newsnewsfilecorp.com·101d ago·Neutral
Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26 Dallas, Texas--(Newsfile Corp. - August 13, 2026) - NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI).
View source ↗ - Newsglobenewswire.com·101d ago·Negative
The Nose Knows: Why NeOnc's Patent Portfolio Could Make NTHI More Than a One-Drug Biotech DENVER, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings' (NASDAQ: NTHI) August 12 headline was impossible to miss, but another interesting solution may be hiding in plain sight: while NeOnc produced encouraging data for one cancer drug, it also generated human clinical evidence around a non-invasive intranasal delivery strategy designed to reach the brain without relying on conventional system…
View source ↗ - Newsglobenewswire.com·102d ago·Neutral
Targeting The Mutant: NTHI's NEO100 Data Could Open a New Front in the Fight Against Brain Cancer DALLAS, Aug. 12, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has delivered the kind of clinical update that can change the conversation around a small biotechnology company: its Phase 2a study of intranasal NEO100 in recurrent IDH1-mutant high-grade glioma met its primary endpoint, with six-month progression-free survival of 48.9% versus a pre-specified 20% benchmark for stan
View source ↗ - Newsnewsfilecorp.com·103d ago·Positive
NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence Houston, Texas--(Newsfile Corp. - August 11, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) is set up for a potential high impact catalyst day with what market observers are describing as a classic triple confluence setup. The company will release topline Phase 2a results for its intranasal NEO100 therapy in recurrent IDH1-mutant high-grade glioma, a difficult-to-treat form of brain cancer on Wednesday, August 12 at 8:30 a.m.
View source ↗
Earnings
Wed, Apr 7(in 5 months)
Consensus estimate $-0.27 per share
Typical surprise -21.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-0.28 vs $-0.25miss
- Mon, Aug 10$-0.58 vs $-0.12miss
- Mon, May 18$-0.38 vs $-0.22miss
- Tue, Mar 31$-0.40 vs $-0.37miss
- Fri, Nov 14$-0.45 vs $-0.37miss
Estimates and results for NTHI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NTHI officers and directors.
- Bought
- $2.0m
- Sold
- $3.8m
46 trades
11 trades
- Heshmatpour Amir Fbought
- Heshmatpour Amir Fbought
- Heshmatpour Amir Fbought
- Chen Thomas Cbought
- Heshmatpour Amir Fbought
- Chen Thomas Cbought
- Heshmatpour Amir Fbought
- Heshmatpour Amir Fbought
32 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NTHI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
